AstraZeneca's Bold Move in Beijing

In a significant development, AstraZeneca has announced a whopping $2.5 billion investment to set up its second strategic research and development (R&D) center in Beijing, marking its sixth worldwide. This ambitious project is expected to employ 1,700 personnel, showcasing the company's strong belief in Beijing's world-class life sciences ecosystem.

Strategic Partnerships and Collaborations

This five-year investment includes a strategic partnership with Beijing's Municipal Government and Economic-Technological Development Area Office. Furthermore, AstraZeneca is set to collaborate with three leading biotech firms: Harbour BioMed, Syneron Bio, and BioKangtai, highlighting the extensive opportunities for collaboration and access to talent in the region.

Commitment to Innovation and Growth in China

"Our $2.5 billion investment underscores our unwavering commitment to China and our confidence in the vibrant life sciences ecosystem here. We are excited about the potential for groundbreaking innovations and the opportunity to contribute to the global healthcare landscape," stated Pascal Soriot, AstraZeneca's Chief Executive Officer.